

# Supplementary Material

## Robust Pharmacodynamic Effect of LY3202626, a Central Nervous System Penetrant, Low Dose BACE1 Inhibitor, in Humans and Nonclinical Species

**Supplementary Table 1.** Clinical CSF and Plasma Exposures

	LY3202626 Geometric Mean (CV%)		
	1.6 mg	10 mg	26 mg
N	5	7	5
Plasma AUC(0-24) (ng•hr/mL)	26.4 (49)	37.2 (157)	307 (101)
CSF AUC(0-24) (ng•hr/mL)	1.08 <sup>a</sup> (19)	2.28 <sup>b</sup> (119)	8.53 (110)
CSF:plasma AUC(0-24) ratio	0.0304 (23)	0.0428 (24)	0.0278 (28)

AUC(0-24), area under the concentration versus time curve from time 0 to 24 h postdose; CSF, cerebrospinal fluid; CV, coefficient of variation; N, number of subjects; <sup>a</sup>N=3; <sup>b</sup>N=5.